These cumulative impacts on the overall immune status of patients may carry substantial clinical consequences, including diminished vaccine responses, and heightened infection risks65, and are likely to influence the efficacy of cancer immunotherapy, given the pivotal role of CD8+ T cells in anticancer immunity66. This evidence concerns the gene CD8A and infection.